Rosiglitazone and Exercise in Patients With Type 2 Diabetes Mellitus
NCT ID: NCT00306176
Last Updated: 2007-04-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
100 participants
INTERVENTIONAL
2005-01-31
2006-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Rosiglitazone
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Poor glycemic control
Exclusion Criteria
* Renal disease
* Liver disease
* Cardiovascular event
40 Years
75 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Athens
OTHER
Aristotle University Of Thessaloniki
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Christos Liapis, PhD,MD
Role: STUDY_CHAIR
University of Athens,Greece
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
AHEPA University Hospital of Thessaloniki
Thessaloniki, Thessaloniki, Greece
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Kadoglou NPE, Korakas E, Lampropoulos S, Maratou E, Kassimis G, Patsourakos N, Plotas P, Moutsatsou P, Lambadiari V. Plasma nesfatin-1 and DDP-4 levels in patients with coronary artery disease: Kozani study. Cardiovasc Diabetol. 2021 Aug 13;20(1):166. doi: 10.1186/s12933-021-01355-x.
Kadoglou NP, Vrabas IS, Kapelouzou A, Angelopoulou N. The association of physical activity with novel adipokines in patients with type 2 diabetes. Eur J Intern Med. 2012 Mar;23(2):137-42. doi: 10.1016/j.ejim.2011.10.020. Epub 2011 Nov 29.
Kadoglou NP, Vrabas IS, Sailer N, Kapelouzou A, Fotiadis G, Noussios G, Karayannacos PE, Angelopoulou N. Exercise ameliorates serum MMP-9 and TIMP-2 levels in patients with type 2 diabetes. Diabetes Metab. 2010 Apr;36(2):144-51. doi: 10.1016/j.diabet.2009.11.004. Epub 2010 Feb 9.
Kadoglou NP, Iliadis F, Angelopoulou N, Sailer N, Fotiadis G, Voliotis K, Vitta I, Liapis CD, Alevizos M. Cardiorespiratory capacity is associated with favourable cardiovascular risk profile in patients with Type 2 diabetes. J Diabetes Complications. 2009 May-Jun;23(3):160-6. doi: 10.1016/j.jdiacomp.2007.12.008. Epub 2008 Apr 16.
Kadoglou NP, Iliadis F, Liapis CD, Perrea D, Angelopoulou N, Alevizos M. Beneficial effects of combined treatment with rosiglitazone and exercise on cardiovascular risk factors in patients with type 2 diabetes. Diabetes Care. 2007 Sep;30(9):2242-4. doi: 10.2337/dc07-0341. Epub 2007 Jun 22. No abstract available.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1975
Identifier Type: -
Identifier Source: org_study_id